Login to MyKarger

New to MyKarger? Click here to sign up.

Login with Facebook

Forgot Password? Reset your password

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login (Shibboleth)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Table of Contents
Vol. 34, No. 1, 2010
Issue release date: January 2010
Section title: Original Paper
Free Access
Neuroepidemiology 2010;34:43–49

The APOE ε4 Allele Is Associated with Incident Mild Cognitive Impairment among Community-Dwelling Older Persons

Boyle P.A.a, d · Buchman A.S.b, d · Wilson R.S.a, b, d · Kelly J.F.c, d · Bennett D.A.b, d
Departments of aBehavioral Sciences, bNeurological Sciences and cInternal Medicine, and dRush Alzheimer’s Disease Center, Rush University Medical Center, Chicago, Ill., USA
email Corresponding Author

Patricia Boyle, PhD

Rush Alzheimer’s Disease Center, Rush University Medical Center

Armour Academic Facility, Suite 1020B

600 South Paulina Street, Chicago, IL 60612 (USA)

Tel. +1 312 942 8749, Fax +1 312 563 4604, E-Mail Patricia_Boyle@rush.edu

Do you have an account?

Login Information

Contact Information

I have read the Karger Terms and Conditions and agree.


Background: The apolipoprotein E (APOE) ε4 allele is a well-known risk factor for the development of Alzheimer’s disease, but little is known about the association of the ε4 allele with incident mild cognitive impairment (MCI). Objective: Test the hypothesis that the ε4 allele is associated with an increased risk of developing MCI. Methods: More than 600 older Catholic clergy members from the Religious Orders Study without any cognitive impairment at baseline underwent APOE genotyping and detailed annual clinical evaluations for up to 16 years of follow-up (mean: 10.17 years; range: 2–16 years) to document incident MCI and rates of decline in global cognition and 5 cognitive domains (i.e. episodic memory, semantic memory, working memory, perceptual speed and visuospatial abilities). Results: During up to 16 years of annual follow-up, 339 of 607 persons (56%) developed MCI. In a proportional hazards model adjusted for age, sex and education, the presence of the APOE ε4 allele was associated with a 1.4-fold increased risk of incident MCI (hazard ratio: 1.36; 95% CI: 1.04, 1.78). Further, this association persisted in analyses that required MCI to persist for at least one year (hazard ratio: 1.50; 95% CI: 1.05, 2.14). Finally, the ε4 allele was associated with an increased rate of decline in global cognition and 4 out of 5 cognitive systems (i.e. episodic memory, semantic memory, working memory and perceptual speed). Conclusion: The presence of the APOE ε4 allele is associated with an increased risk of MCI and a more rapid rate of cognitive decline in old age.

© 2009 S. Karger AG, Basel

Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: May 17, 2009
Accepted: September 07, 2009
Published online: November 11, 2009
Issue release date: January 2010

Number of Print Pages: 7
Number of Figures: 2
Number of Tables: 2

ISSN: 0251-5350 (Print)
eISSN: 1423-0208 (Online)

For additional information: http://www.karger.com/NED

Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.